On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. In its official statement, the Biotechnology Innovation Organization (BIO) shares why the CMS Decision is an enormous setback for Alzheimer’s patients and a dangerous infringement on FDA’s Scientific Autonomy.
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample
The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine.
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental healthContinue reading
The SBIR/STTR Programs are currently set to expire on September 30, 2022. It would be damaging to American innovation and competitiveness if these programs were to expire before a full reauthorization can be passed. The SBIR/STTR Programs enable small businesses to develop and commercialize new innovative technologies and have a proven track record of promoting competition through a merit-based application process. Since their establishment in 1982, these programs have provided over 179,000 awards, totaling more than $54.3 billion, to U.S. small businesses. A study by the National Academy of Sciences found a commercialization rate of 50-60% for SBIR/STTR investments. You can see the impact of SBIR/STTR in Arizona by clicking here.
TUCSON, Ariz., March 31, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”), establishing the utility of its novel approach to drug discovery utilizing its proprietary platform.Continue reading
TEMPE, Ariz. — More than two years into a global pandemic, the clear need for innovative medical breakthroughs has never been more obvious. The Mayo Clinic and Arizona State University (ASU) MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, was designed to help empower medical startups to better navigate challenges while bringing forth life-changing health innovations. The third cohort of this program launched on March 28.Continue reading
On March 29, 2022, Arizona’s Senate Appropriations Committee voted unanimously to give a Do Pass as Amended recommendation for HB2039. The next step in the process is review by the Senate Rules Committee.
If HB2039 successfully completes the legislative process and is signed into law by the Governor, it will establish the statutory framework for the Arizona Health Innovation Trust Fund within the Arizona State Treasurer’s Office with the State Treasurer as Trustee. Continue reading